Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Winfried Wels

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
International Journal of Cancer|January 5, 2002
Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxinsMathias Schmidt, Winfried Wels
Current Molecular Medicine|July 23, 2004
Therapeutic antibodiesBernd Groner, Cord Hartmann, Winfried Wels
Virology|November 21, 2002
Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cellsOtto Erlwein, Winfried Wels, Barbara S Schnierle
Biochemical and Biophysical Research Communications|October 10, 2002
Delivery of nucleic acid into mammalian cells by anthrax toxinReetika Gaur, Pradeep K Gupta, Anita Goyal, et al.
Oncogene|March 12, 2003
Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptorStephen Hyland, Roger R Beerli, Carlos F Barbas, et al.
Cancer Immunology, Immunotherapy : CII|January 6, 2004
Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectorsWinfried Wels, Markus Biburger, Tina Müller, et al.
Blood|August 1, 2002
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destructionChristoph Uherek, Torsten Tonn, Barbara Uherek, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targetingJiri Eitler, Natalie Wotschel, Nicole Miller, et al.
The Journal of Biological Chemistry|October 20, 2001
Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymeraseDarius Moradpour, Elke Bieck, Thomas Hügle, et al.
European Radiology|December 24, 2004
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imagingHeike E Daldrup-Link, Reinhardt Meier, Martina Rudelius, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Journal of Cancer|January 5, 2002
Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxinsMathias Schmidt, Winfried Wels
Current Molecular Medicine|July 23, 2004
Therapeutic antibodiesBernd Groner, Cord Hartmann, Winfried Wels
Virology|November 21, 2002
Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cellsOtto Erlwein, Winfried Wels, Barbara S Schnierle
Biochemical and Biophysical Research Communications|October 10, 2002
Delivery of nucleic acid into mammalian cells by anthrax toxinReetika Gaur, Pradeep K Gupta, Anita Goyal, et al.
Oncogene|March 12, 2003
Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptorStephen Hyland, Roger R Beerli, Carlos F Barbas, et al.
Cancer Immunology, Immunotherapy : CII|January 6, 2004
Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectorsWinfried Wels, Markus Biburger, Tina Müller, et al.
Blood|August 1, 2002
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destructionChristoph Uherek, Torsten Tonn, Barbara Uherek, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targetingJiri Eitler, Natalie Wotschel, Nicole Miller, et al.
The Journal of Biological Chemistry|October 20, 2001
Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymeraseDarius Moradpour, Elke Bieck, Thomas Hügle, et al.
European Radiology|December 24, 2004
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imagingHeike E Daldrup-Link, Reinhardt Meier, Martina Rudelius, et al.
Pageof 1